Ocata Therapeutics Inc  

(Public, NASDAQ:OCAT)   Watch this stock  
Find more results for OTC:ACTC
5.27
+0.23 (4.56%)
Jun 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.04 - 5.30
52 week 4.88 - 12.73
Open 5.10
Vol / Avg. 381,315.00/533,194.00
Mkt cap 218.96M
P/E     -
Div/yield     -
EPS -1.05
Shares 41.96M
Beta 1.04
Inst. own 1%
Jul 8, 2015
Ocata Therapeutics Inc at Cantor Fitzgerald Inaugural Healthcare Conference - 11:15AM EDT - Add to calendar
Jun 1, 2015
Ocata Therapeutics Inc at Jefferies Global Healthcare Conference
May 7, 2015
Q1 2015 Ocata Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -17825.11% -22009.72%
Operating margin -17840.31% -22249.30%
EBITD margin - -13499.45%
Return on average assets -531.69% -720.53%
Return on average equity - -
Employees 37 -
CDP Score - -

Address

33 Locke Dr
MARLBOROUGH, MA 01752-1167
United States - Map
+1-508-7561212 (Phone)
+1-508-2292333 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Officers and directors

Michael Thomas Heffernan Independent Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Edward Myles CPA Chief Financial Officer, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
LeRoux Jooste Senior Vice President - Business Development, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Robert P. Lanza M.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
John Heffernan Vice President - Manufacturing
Bio & Compensation  - Reuters
Eddy Anglade M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Robert S. Langer Independent Director
Age: 66
Bio & Compensation  - Reuters
Zohar Loshitzer Independent Director
Age: 57
Bio & Compensation  - Reuters
Gregory D. Perry Independent Director
Age: 54
Bio & Compensation  - Reuters